Clinical Trial

Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression

Recruiting
View on ClinicalTrials.gov →
Summary
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-11-18; most recent amendment 2025-10-17.
Trial Details
NCT Number NCT05630963
Lead Sponsor Mclean Hospital
Collaborators: National Institute of Mental Health (NIMH)
Conditions Major Depressive Disorder
Enrollment 228 participants
Start Date 2021-12-29
Primary Completion 2026-10-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-10-21